Literature DB >> 26111805

Comparison of cardiac MRI and 18F-FDG positron emission tomography manifestations and regional response to corticosteroid therapy in newly diagnosed cardiac sarcoidosis with complet heart block.

Makoto Orii1, Kumiko Hirata2, Takashi Tanimoto2, Shingo Ota2, Yasutsugu Shiono2, Takashi Yamano2, Yoshiki Matsuo2, Yasushi Ino2, Tomoyuki Yamaguchi2, Takashi Kubo2, Atsushi Tanaka2, Takashi Akasaka2.   

Abstract

BACKGROUND: Complete heart block (CHB) caused by myocardial inflammation is a serious consequence of cardiac sarcoidosis (CS) that requires early diagnosis for effective anti-inflammatory treatment.
OBJECTIVE: This study aimed to clarify the cardiac magnetic resonance imaging (MRI) and (18)F-fluoro-2-deoxyglucose positron emission tomography ((18)F-FDG PET) manifestations of newly diagnosed CS with CHB and to assess whether certain imaging features could predict responders to corticosteroid therapy.
METHODS: Fifteen newly diagnosed CS patients with CHB and 17 without CHB were examined. We defined abnormal (18)F-FDG uptake on (18)F-FDG PET and increased T2-weighted signal on cardiac MRI as signs of myocardial inflammation and delayed enhancement (DE) on cardiac MRI as a sign of myocardial fibrosis. Ten CHB+ patients were then treated with corticosteroids.
RESULTS: The CHB+ group showed higher (18)F-FDG uptake and increased T2-weighted signal in the interventricular septum, which involves the electrical pathway of atrioventricular conduction, than the CHB- group (P = .001 and P < .0001, respectively), whereas there was no group difference in DE (P = .232). Six corticosteroid-treated patients recovered from CHB; all had exhibited increased T2-weighted signal, (18)F-FDG uptake, and DE in the interventricular septum before therapy. In contrast, among the 4 patients without recovery, 2 showed no abnormal (18)F-FDG uptake and 3 had no increased T2-weighted signal in the interventricular septum, but all showed DE. The 2 patients without recovery with abnormal (18)F-FDG uptake showed wall thinning in the interventricular septum.
CONCLUSION: Focal inflammation in the interventricular septum was associated with CHB and might predict recovery from CHB after corticosteroids if it coexists with preserved wall thickness.
Copyright © 2015 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (18)F-fluoro-2-deoxyglucose positron emission tomography; Cardiac sarcoidosis; Complete heart block; Inflammation; Magnetic resonance imaging

Mesh:

Substances:

Year:  2015        PMID: 26111805     DOI: 10.1016/j.hrthm.2015.06.032

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  29 in total

1.  Advanced cardiovascular imaging for the evaluation of cardiac sarcoidosis.

Authors:  Paco E Bravo; Amitoj Singh; Marcelo F Di Carli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2018-11-02       Impact factor: 5.952

2.  Multimodality imaging in the diagnosis and management of cardiac sarcoidosis.

Authors:  Shant J Manoushagian; Vladimir Lakhter; Pravin V Patil
Journal:  J Nucl Cardiol       Date:  2016-11-11       Impact factor: 5.952

3.  A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology.

Authors:  Riemer H J A Slart; Andor W J M Glaudemans; Patrizio Lancellotti; Fabien Hyafil; Ron Blankstein; Ronald G Schwartz; Wael A Jaber; Raymond Russell; Alessia Gimelli; François Rouzet; Marcus Hacker; Olivier Gheysens; Sven Plein; Edward J Miller; Sharmila Dorbala; Erwan Donal
Journal:  J Nucl Cardiol       Date:  2018-02       Impact factor: 5.952

4.  Cardiac sarcoidosis, the complete atrioventricular block of which was completely recovered by intravenous steroid pulse therapy.

Authors:  Hiroaki Watanabe; Kazuo Eguchi; Toshinobu Saitou; Masahisa Shimpo; Michiaki Hiroe; Kazuomi Kario
Journal:  J Cardiol Cases       Date:  2015-10-20

5.  T wave amplitude in lead aVR as a novel diagnostic marker for cardiac sarcoidosis.

Authors:  Yoshihiro Tanaka; Tetsuo Konno; Shohei Yoshida; Toyonobu Tsuda; Kenji Sakata; Hiroshi Furusho; Masayuki Takamura; Kenichi Yoshimura; Masakazu Yamagishi; Kenshi Hayashi
Journal:  Heart Vessels       Date:  2016-07-27       Impact factor: 2.037

6.  The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis.

Authors:  Azadeh Ahmadian; Sumeet Pawar; Praveen Govender; Jeffrey Berman; Frederick L Ruberg; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2016-07-25       Impact factor: 5.952

Review 7.  Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis.

Authors:  G Cameron Coleman; Peter W Shaw; Pelbreton C Balfour; Jorge A Gonzalez; Christopher M Kramer; Amit R Patel; Michael Salerno
Journal:  JACC Cardiovasc Imaging       Date:  2016-07-20

Review 8.  Isolated cardiac sarcoidosis: A focused review of an under-recognized entity.

Authors:  David R Okada; Paco E Bravo; Tomas Vita; Vikram Agarwal; Michael T Osborne; Viviany R Taqueti; Hicham Skali; Panithaya Chareonthaitawee; Sharmila Dorbala; Garrick Stewart; Marcelo Di Carli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2016-09-09       Impact factor: 5.952

9.  Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis.

Authors:  Tomas Vita; David R Okada; Mahdi Veillet-Chowdhury; Paco E Bravo; Erin Mullins; Edward Hulten; Mukta Agrawal; Rachna Madan; Viviany R Taqueti; Michael Steigner; Hicham Skali; Raymond Y Kwong; Garrick C Stewart; Sharmila Dorbala; Marcelo F Di Carli; Ron Blankstein
Journal:  Circ Cardiovasc Imaging       Date:  2018-01       Impact factor: 7.792

Review 10.  Radionuclide Imaging Applications in Cardiomyopathies and Heart Failure.

Authors:  Matthew E Harinstein; Prem Soman
Journal:  Curr Cardiol Rep       Date:  2016-03       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.